+关注
Winalot
暂无个人介绍
IP属地:未知
72
关注
6
粉丝
0
主题
0
勋章
主贴
热门
Winalot
2021-11-15
Nice for cohu
抱歉,原内容已删除
Winalot
2021-12-06
Meta is the new
抱歉,原内容已删除
Winalot
2021-11-27
Good for vaccine manufacturers but bad for mankind
Vaccine stocks continued to rise in early trading, Moderna shares surged more than 23%.
Winalot
2021-09-29
Time to pick up stocks
抱歉,原内容已删除
Winalot
2021-12-04
Nice
5 Warren Buffett Stocks Are Screaming Buys in December
Winalot
2021-10-08
Come come come. More good news please
抱歉,原内容已删除
Winalot
2021-12-06
Congrats
@Hansen77:
$Apple(AAPL)$
This is my Apple share.
去老虎APP查看更多动态
{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":4092740792654610,"uuid":"4092740792654610","gmtCreate":1629638451515,"gmtModify":1630401748602,"name":"Winalot","pinyin":"winalot","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/8b310145827ffdca4a18cd3a698ce65e","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":6,"headSize":72,"tweetSize":9,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖(非转发)","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":1,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":608743078,"gmtCreate":1638795194963,"gmtModify":1638795951176,"author":{"id":"4092740792654610","authorId":"4092740792654610","name":"Winalot","avatar":"https://static.tigerbbs.com/8b310145827ffdca4a18cd3a698ce65e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Congrats ","listText":"Congrats ","text":"Congrats","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/608743078","repostId":"608195827","repostType":1,"repost":{"id":608195827,"gmtCreate":1638661527701,"gmtModify":1638704925237,"author":{"id":"3583908378875163","authorId":"3583908378875163","name":"Hansen77","avatar":"https://static.tigerbbs.com/ce6fe6bb3c85a7f6f1d96e2469d290b4","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>This is my Apple share.","listText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>This is my Apple share.","text":"$Apple(AAPL)$This is my Apple share.","images":[{"img":"https://static.tigerbbs.com/7a8dd3644d1ba34067f4421ee50a6e74","width":"1080","height":"1920"}],"top":1,"highlighted":2,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/608195827","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":458,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":608749282,"gmtCreate":1638795158663,"gmtModify":1638795950059,"author":{"id":"4092740792654610","authorId":"4092740792654610","name":"Winalot","avatar":"https://static.tigerbbs.com/8b310145827ffdca4a18cd3a698ce65e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Meta is the new ","listText":"Meta is the new ","text":"Meta is the new","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/608749282","repostId":"2189186504","repostType":4,"repost":{"id":"2189186504","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1638794422,"share":"https://www.laohu8.com/m/news/2189186504?lang=&edition=full","pubTime":"2021-12-06 20:40","market":"us","language":"en","title":"Google, Meta dominate as digital propels global advertising growth -forecasts","url":"https://stock-news.laohu8.com/highlight/detail?id=2189186504","media":"Reuters","summary":"Dec 6 (Reuters) - The global advertising industry will notch higher growth this year than previously","content":"<p>Dec 6 (Reuters) - The global advertising industry will notch higher growth this year than previously expected as brands are relying more heavily on search engine and social media companies such as Alphabet Inc's Google and <a href=\"https://laohu8.com/S/FB\">Meta Platforms</a> Inc to reach customers during the pandemic, according to two ad industry forecasts released on Monday.</p>\n<p>Despite a year marked by worldwide supply chain disruptions that delayed products from reaching shelves and a user privacy clampdown by Apple Inc that many feared would disrupt mobile advertising, brands have continued to advertise online as in-store shopping has been slow to return due to the ongoing pandemic, said Jonathan Barnard, director of global intelligence at advertising firm Zenith, which published an ad expenditure forecast on Monday.</p>\n<p>New businesses formed during the pandemic needed to advertise to find customers, while others likely maintained ad spending to stay in front of consumers' minds, said Brian Wieser, global president of business intelligence at ad agency GroupM.</p>\n<p>GroupM forecast global ad spending to grow 22.5% in 2021 from the previous year, while Zenith estimated growth of 15.6% -- both estimates were revised up from previous expectations.</p>\n<p>Global ad spending is expected to increase by about 9% in 2022, according to the reports.</p>\n<p>The growth has been a boon for Alphabet, Meta and Amazon.com Inc, major sellers of digital ads and which now account for more than half of all advertising spending outside of China, an increase from closer to 40% in 2019, GroupM said.</p>\n<p>It also comes as Alphabet and Meta, the company formerly known as Facebook, both face antitrust investigations in the United States and Europe.</p>\n<p>The need for marketers to directly reach consumers has also led to the success of retailers like Walmart, Target and Kroger to rapidly grow their own ad sales businesses, allowing brands to use their shopper data to target more customers. This form of advertising grew 47% this year to total $77 billion and is expected to grow to $143 billion by 2024, according to Zenith.</p>\n<p>Retail media networks have been established in China for the more than a decade, but its rise in other markets has been remarkable, Barnard said.</p>\n<p>\"In the last five years, it has grown explosively out of nowhere outside of China,\" he said.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Google, Meta dominate as digital propels global advertising growth -forecasts</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGoogle, Meta dominate as digital propels global advertising growth -forecasts\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-12-06 20:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Dec 6 (Reuters) - The global advertising industry will notch higher growth this year than previously expected as brands are relying more heavily on search engine and social media companies such as Alphabet Inc's Google and <a href=\"https://laohu8.com/S/FB\">Meta Platforms</a> Inc to reach customers during the pandemic, according to two ad industry forecasts released on Monday.</p>\n<p>Despite a year marked by worldwide supply chain disruptions that delayed products from reaching shelves and a user privacy clampdown by Apple Inc that many feared would disrupt mobile advertising, brands have continued to advertise online as in-store shopping has been slow to return due to the ongoing pandemic, said Jonathan Barnard, director of global intelligence at advertising firm Zenith, which published an ad expenditure forecast on Monday.</p>\n<p>New businesses formed during the pandemic needed to advertise to find customers, while others likely maintained ad spending to stay in front of consumers' minds, said Brian Wieser, global president of business intelligence at ad agency GroupM.</p>\n<p>GroupM forecast global ad spending to grow 22.5% in 2021 from the previous year, while Zenith estimated growth of 15.6% -- both estimates were revised up from previous expectations.</p>\n<p>Global ad spending is expected to increase by about 9% in 2022, according to the reports.</p>\n<p>The growth has been a boon for Alphabet, Meta and Amazon.com Inc, major sellers of digital ads and which now account for more than half of all advertising spending outside of China, an increase from closer to 40% in 2019, GroupM said.</p>\n<p>It also comes as Alphabet and Meta, the company formerly known as Facebook, both face antitrust investigations in the United States and Europe.</p>\n<p>The need for marketers to directly reach consumers has also led to the success of retailers like Walmart, Target and Kroger to rapidly grow their own ad sales businesses, allowing brands to use their shopper data to target more customers. This form of advertising grew 47% this year to total $77 billion and is expected to grow to $143 billion by 2024, according to Zenith.</p>\n<p>Retail media networks have been established in China for the more than a decade, but its rise in other markets has been remarkable, Barnard said.</p>\n<p>\"In the last five years, it has grown explosively out of nowhere outside of China,\" he said.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"WMT":"沃尔玛","KR":"克罗格","CASH":"米塔金融","BK4211":"区域性银行","TGT":"塔吉特","GOOGL":"谷歌A","AMZN":"亚马逊","AAPL":"苹果"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2189186504","content_text":"Dec 6 (Reuters) - The global advertising industry will notch higher growth this year than previously expected as brands are relying more heavily on search engine and social media companies such as Alphabet Inc's Google and Meta Platforms Inc to reach customers during the pandemic, according to two ad industry forecasts released on Monday.\nDespite a year marked by worldwide supply chain disruptions that delayed products from reaching shelves and a user privacy clampdown by Apple Inc that many feared would disrupt mobile advertising, brands have continued to advertise online as in-store shopping has been slow to return due to the ongoing pandemic, said Jonathan Barnard, director of global intelligence at advertising firm Zenith, which published an ad expenditure forecast on Monday.\nNew businesses formed during the pandemic needed to advertise to find customers, while others likely maintained ad spending to stay in front of consumers' minds, said Brian Wieser, global president of business intelligence at ad agency GroupM.\nGroupM forecast global ad spending to grow 22.5% in 2021 from the previous year, while Zenith estimated growth of 15.6% -- both estimates were revised up from previous expectations.\nGlobal ad spending is expected to increase by about 9% in 2022, according to the reports.\nThe growth has been a boon for Alphabet, Meta and Amazon.com Inc, major sellers of digital ads and which now account for more than half of all advertising spending outside of China, an increase from closer to 40% in 2019, GroupM said.\nIt also comes as Alphabet and Meta, the company formerly known as Facebook, both face antitrust investigations in the United States and Europe.\nThe need for marketers to directly reach consumers has also led to the success of retailers like Walmart, Target and Kroger to rapidly grow their own ad sales businesses, allowing brands to use their shopper data to target more customers. This form of advertising grew 47% this year to total $77 billion and is expected to grow to $143 billion by 2024, according to Zenith.\nRetail media networks have been established in China for the more than a decade, but its rise in other markets has been remarkable, Barnard said.\n\"In the last five years, it has grown explosively out of nowhere outside of China,\" he said.","news_type":1},"isVote":1,"tweetType":1,"viewCount":296,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":601772943,"gmtCreate":1638577213231,"gmtModify":1638577213231,"author":{"id":"4092740792654610","authorId":"4092740792654610","name":"Winalot","avatar":"https://static.tigerbbs.com/8b310145827ffdca4a18cd3a698ce65e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/601772943","repostId":"2188528084","repostType":4,"repost":{"id":"2188528084","pubTimestamp":1638543717,"share":"https://www.laohu8.com/m/news/2188528084?lang=&edition=full","pubTime":"2021-12-03 23:01","market":"us","language":"en","title":"5 Warren Buffett Stocks Are Screaming Buys in December","url":"https://stock-news.laohu8.com/highlight/detail?id=2188528084","media":"Motley Fool","summary":"Riding the Oracle of Omaha's coattails is often a moneymaking proposition.","content":"<p>Making money for shareholders has been in Warren Buffett's blood since taking over as CEO of <b>Berkshire Hathaway</b> (NYSE:BRK.A)(NYSE:BRK.B) in 1965. Over that time, he's led Berkshire to an average annual gain of about 20%, which translates into aggregate gains, including the year-to-date performance of the Class A shares (BRK.A), of approximately 3,500,000%. Gains like this are why the investing world pays close attention to what the Oracle of Omaha is buying and selling.</p>\n<p>Based on the latest 13F filing with the Securities and Exchange Commission, Berkshire Hathaway has stakes in 45 securities. Among these 45 holdings, five Warren Buffett stocks stand out as screaming buys in December.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/e92116e97f06291ec28eda85974acb1b\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Berkshire Hathaway CEO Warren Buffett. Image source: The Motley Fool.</span></p>\n<h2>Amazon</h2>\n<p>While I'm well aware this isn't going to win any points for originality, e-commerce kingpin <b>Amazon</b> (NASDAQ:AMZN) remains a surefire stock to own in Buffett's portfolio.</p>\n<p>Most people are familiar with Amazon for its dominant online marketplace. According to an August report from eMarketer, Amazon is expected to handle 41.4% of all U.S. online sales in 2021. That's about 34 percentage points higher than the next-closest competitor. The key, though, is that the company has signed up 200 million people to a Prime membership worldwide. The annual fees collected from these members helps to buoy razor-thin retail margins and allows Amazon to consistently undercut brick-and-mortar retailers on price.</p>\n<p>However, the company's future rests with its considerably higher-margin segments, such as cloud infrastructure services. Amazon Web Services (AWS) accounted for only 13.4% of net sales in the third quarter, yet contributed 61.8% of the company's operating income. Even with online sales slowing as coronavirus vaccination rates tick higher and life returns to some semblance of normal, Amazon's critical highest-margin segments (AWS, subscriptions, and advertising) continue to grow rapidly.</p>\n<p>If Amazon were to simply hit the median price-to-operating cash flow it's been trading at for the past 11 years, we could be looking at a $10,000 a share company by mid-decade.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/b18b49b2b35da2fc49e0a83b883d1c22\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Bristol Myers Squibb</h2>\n<p>Another Warren Buffett stock that's quickly become a screaming buy is pharmaceutical company <b>Bristol Myers Squibb</b> (NYSE:BMY).</p>\n<p>Bristol Myers' success is dependent on organically developing and growing its brand-name pharmaceutical portfolio, as well as leaning on acquisitions to push the needle higher.</p>\n<p>From an internal development perspective, some of the company's biggest wins include cancer immunotherapy Opdivo and oral anticoagulant Eliquis -- the latter of which was developed with <b>Pfizer</b>. Eliquis should push for $10 billion in sales for Bristol Myers this year, while Opdivo hit $7 billion in revenue last year. Opdivo is particularly intriguing given that it's being examined in dozens of clinical trials and has already received approval for 10 indications in the U.S. Label expansion opportunities, pricing power, and improved cancer screening diagnostics all have the potential to make this a $10 billion a year therapy.</p>\n<p>Bristol Myers also made waves with its November 2019 acquisition of cancer and immunology drugmaker Celgene. Buying Celgene added a handful of blockbuster drugs to Bristol's portfolio, including multiple myeloma treatment Revlimid, which will potentially top $13 billion in 2021 sales. Revlimid is protected from an onslaught of generic competition for four more years, which means Bristol Myers will be generating bountiful cash flow in the meantime.</p>\n<p>At just 7 times consensus forward-year earnings per share, it's an absolute steal.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/a295212aa2b7c99c921b8afa2a4aa3a2\" tg-width=\"700\" tg-height=\"467\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2><a href=\"https://laohu8.com/S/V\">Visa</a></h2>\n<p>The recent sell-off in payment processing behemoth <b>Visa</b> (NYSE:V) makes it a screaming buy, too.</p>\n<p>Over the past couple of months, Wall Street and investors have raised concerns about payment facilitators like <b>Square</b> or cryptocurrencies eating into Visa's dominance. However, these concerns seem unfounded given Visa's utter dominance of the processing space. As of 2018, it held a 53% share of U.S. credit card network purchase volume, which was more than 30 percentage points higher than the next-closest competitor. I should also mention the U.S. is the leading market for consumption in the world.</p>\n<p>Visa's outperformance is also a function of its lending avoidance. By sticking to the processing side of the equation, the company avoids having to set aside capital to cover credit delinquencies during recessions. Not having to cover credit/loan losses is a big reason why Visa rebounds faster than other financial stocks and maintains a profit margin north of 50%.</p>\n<p>And have I mentioned that Visa is <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the smartest ways to play rapidly rising inflation? Since the company's fees are tied to the price of goods and services, its revenue and profits will grow as the price for goods and services rises.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1c5a0257bdd17a5ff3cf22a10de43ce0\" tg-width=\"700\" tg-height=\"467\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Teva Pharmaceutical Industries</h2>\n<p>The cheapest stock in Warren Buffett's portfolio, brand-name and generic-drug company <b>Teva Pharmaceutical Industries</b> (NYSE:TEVA), is begging to be bought as well. Teva can currently be purchased for a little more than 3 times Wall Street's consensus earnings per share in 2021 and 2022.</p>\n<p>Unlike Amazon, Bristol Myers, and Visa, Teva hasn't been firing on all cylinders. Since 2016, the company settled a bribery scandal, buried itself in debt after overpaying for generic-drugmaker Actavis, and has faced a mountain of litigation concerning its role in the opioid epidemic. But while there's reason to not give Teva a valuation premium, an earnings multiple of 3 is overly pessimistic given the steps being taken to right the ship.</p>\n<p>In late 2017, Kare Schultz took over as CEO. He's a turnaround specialist who's taken clear steps to improve the business. During his tenure, net debt has been reduced from over $34 billion to around $22 billion, and annual operating expenses have been cut by a double-digit percentage. Teva is leaner than it's been in years and is capable of maintaining annual operating cash flow of $2 billion (or higher).</p>\n<p>Furthermore, there's light at the end of the tunnel when it comes to opioid litigation. A trial in California recently went in favor of drugmakers, which could put some bargaining power back in Teva's court. If Schultz can negotiate a national settlement where free or reduced-cost medicine, not cash, is the lure, Teva could probably double very quickly.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/7343c3ce7330b86321a8ec9384d4baea\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Bank of America</h2>\n<p>The final Warren Buffett stock to buy hand over fist in December is banking juggernaut <b>Bank of America</b> (NYSE:BAC).</p>\n<p>Bank stocks like BofA are on the cusp of hitting their growth sweet spot. With inflation picking up, the Federal Reserve will more than likely need to act in 2022 or 2023 to raise interest rates. Boosting the federal funds target rate will lift the net interest income-earning potential of banks with outstanding variable-rate loans.</p>\n<p>Among money-center banks, none is more interest-sensitive than Bank of America. The company's third-quarter earnings presentation points out that a 100-basis-point parallel shift in the interest rate yield curve would generate an estimated $7.2 billion in added net interest income over 12 months. Although we're unlikely to see a 100-basis-point shift in 12 months, we are on the verge of seeing higher interest rates significantly bolster BofA's profit potential.</p>\n<p>The other impressive aspect of Warren Buffett's second-largest holding is its digitization efforts. Though you probably don't think of Bank of America as a tech-savvy business, the number of digital active users has grown to nearly 41 million, with 43% of all sales in the third quarter coming from online or mobile banking. This push to digitize has allowed the company to consolidate some of its branches in order to reduce costs.</p>\n<p>Bank of America should be a no-brainer buy as it enters the sweet spot of its growth cycle.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Warren Buffett Stocks Are Screaming Buys in December</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Warren Buffett Stocks Are Screaming Buys in December\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-03 23:01 GMT+8 <a href=https://www.fool.com/investing/2021/12/03/5-warren-buffett-stocks-screaming-buys-in-december/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Making money for shareholders has been in Warren Buffett's blood since taking over as CEO of Berkshire Hathaway (NYSE:BRK.A)(NYSE:BRK.B) in 1965. Over that time, he's led Berkshire to an average ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/03/5-warren-buffett-stocks-screaming-buys-in-december/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4504":"桥水持仓","TEVA":"梯瓦制药","BK4548":"巴美列捷福持仓","V":"Visa","BK4176":"多领域控股","BK4532":"文艺复兴科技持仓","BK4554":"元宇宙及AR概念","BK4106":"数据处理与外包服务","BK4553":"喜马拉雅资本持仓","BRK.A":"伯克希尔","BK4534":"瑞士信贷持仓","BK4507":"流媒体概念","BRK.B":"伯克希尔B","BAC":"美国银行","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","BK4566":"资本集团","BMY":"施贵宝","BK4557":"大麻股","BK4524":"宅经济概念","BK4535":"淡马锡持仓","BK4559":"巴菲特持仓","BK4527":"明星科技股","BK4538":"云计算","BK4550":"红杉资本持仓","AMZN":"亚马逊","BK4122":"互联网与直销零售","BK4503":"景林资产持仓","BK4551":"寇图资本持仓","BK4207":"综合性银行","BK4561":"索罗斯持仓"},"source_url":"https://www.fool.com/investing/2021/12/03/5-warren-buffett-stocks-screaming-buys-in-december/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2188528084","content_text":"Making money for shareholders has been in Warren Buffett's blood since taking over as CEO of Berkshire Hathaway (NYSE:BRK.A)(NYSE:BRK.B) in 1965. Over that time, he's led Berkshire to an average annual gain of about 20%, which translates into aggregate gains, including the year-to-date performance of the Class A shares (BRK.A), of approximately 3,500,000%. Gains like this are why the investing world pays close attention to what the Oracle of Omaha is buying and selling.\nBased on the latest 13F filing with the Securities and Exchange Commission, Berkshire Hathaway has stakes in 45 securities. Among these 45 holdings, five Warren Buffett stocks stand out as screaming buys in December.\nBerkshire Hathaway CEO Warren Buffett. Image source: The Motley Fool.\nAmazon\nWhile I'm well aware this isn't going to win any points for originality, e-commerce kingpin Amazon (NASDAQ:AMZN) remains a surefire stock to own in Buffett's portfolio.\nMost people are familiar with Amazon for its dominant online marketplace. According to an August report from eMarketer, Amazon is expected to handle 41.4% of all U.S. online sales in 2021. That's about 34 percentage points higher than the next-closest competitor. The key, though, is that the company has signed up 200 million people to a Prime membership worldwide. The annual fees collected from these members helps to buoy razor-thin retail margins and allows Amazon to consistently undercut brick-and-mortar retailers on price.\nHowever, the company's future rests with its considerably higher-margin segments, such as cloud infrastructure services. Amazon Web Services (AWS) accounted for only 13.4% of net sales in the third quarter, yet contributed 61.8% of the company's operating income. Even with online sales slowing as coronavirus vaccination rates tick higher and life returns to some semblance of normal, Amazon's critical highest-margin segments (AWS, subscriptions, and advertising) continue to grow rapidly.\nIf Amazon were to simply hit the median price-to-operating cash flow it's been trading at for the past 11 years, we could be looking at a $10,000 a share company by mid-decade.\nImage source: Getty Images.\nBristol Myers Squibb\nAnother Warren Buffett stock that's quickly become a screaming buy is pharmaceutical company Bristol Myers Squibb (NYSE:BMY).\nBristol Myers' success is dependent on organically developing and growing its brand-name pharmaceutical portfolio, as well as leaning on acquisitions to push the needle higher.\nFrom an internal development perspective, some of the company's biggest wins include cancer immunotherapy Opdivo and oral anticoagulant Eliquis -- the latter of which was developed with Pfizer. Eliquis should push for $10 billion in sales for Bristol Myers this year, while Opdivo hit $7 billion in revenue last year. Opdivo is particularly intriguing given that it's being examined in dozens of clinical trials and has already received approval for 10 indications in the U.S. Label expansion opportunities, pricing power, and improved cancer screening diagnostics all have the potential to make this a $10 billion a year therapy.\nBristol Myers also made waves with its November 2019 acquisition of cancer and immunology drugmaker Celgene. Buying Celgene added a handful of blockbuster drugs to Bristol's portfolio, including multiple myeloma treatment Revlimid, which will potentially top $13 billion in 2021 sales. Revlimid is protected from an onslaught of generic competition for four more years, which means Bristol Myers will be generating bountiful cash flow in the meantime.\nAt just 7 times consensus forward-year earnings per share, it's an absolute steal.\nImage source: Getty Images.\nVisa\nThe recent sell-off in payment processing behemoth Visa (NYSE:V) makes it a screaming buy, too.\nOver the past couple of months, Wall Street and investors have raised concerns about payment facilitators like Square or cryptocurrencies eating into Visa's dominance. However, these concerns seem unfounded given Visa's utter dominance of the processing space. As of 2018, it held a 53% share of U.S. credit card network purchase volume, which was more than 30 percentage points higher than the next-closest competitor. I should also mention the U.S. is the leading market for consumption in the world.\nVisa's outperformance is also a function of its lending avoidance. By sticking to the processing side of the equation, the company avoids having to set aside capital to cover credit delinquencies during recessions. Not having to cover credit/loan losses is a big reason why Visa rebounds faster than other financial stocks and maintains a profit margin north of 50%.\nAnd have I mentioned that Visa is one of the smartest ways to play rapidly rising inflation? Since the company's fees are tied to the price of goods and services, its revenue and profits will grow as the price for goods and services rises.\nImage source: Getty Images.\nTeva Pharmaceutical Industries\nThe cheapest stock in Warren Buffett's portfolio, brand-name and generic-drug company Teva Pharmaceutical Industries (NYSE:TEVA), is begging to be bought as well. Teva can currently be purchased for a little more than 3 times Wall Street's consensus earnings per share in 2021 and 2022.\nUnlike Amazon, Bristol Myers, and Visa, Teva hasn't been firing on all cylinders. Since 2016, the company settled a bribery scandal, buried itself in debt after overpaying for generic-drugmaker Actavis, and has faced a mountain of litigation concerning its role in the opioid epidemic. But while there's reason to not give Teva a valuation premium, an earnings multiple of 3 is overly pessimistic given the steps being taken to right the ship.\nIn late 2017, Kare Schultz took over as CEO. He's a turnaround specialist who's taken clear steps to improve the business. During his tenure, net debt has been reduced from over $34 billion to around $22 billion, and annual operating expenses have been cut by a double-digit percentage. Teva is leaner than it's been in years and is capable of maintaining annual operating cash flow of $2 billion (or higher).\nFurthermore, there's light at the end of the tunnel when it comes to opioid litigation. A trial in California recently went in favor of drugmakers, which could put some bargaining power back in Teva's court. If Schultz can negotiate a national settlement where free or reduced-cost medicine, not cash, is the lure, Teva could probably double very quickly.\nImage source: Getty Images.\nBank of America\nThe final Warren Buffett stock to buy hand over fist in December is banking juggernaut Bank of America (NYSE:BAC).\nBank stocks like BofA are on the cusp of hitting their growth sweet spot. With inflation picking up, the Federal Reserve will more than likely need to act in 2022 or 2023 to raise interest rates. Boosting the federal funds target rate will lift the net interest income-earning potential of banks with outstanding variable-rate loans.\nAmong money-center banks, none is more interest-sensitive than Bank of America. The company's third-quarter earnings presentation points out that a 100-basis-point parallel shift in the interest rate yield curve would generate an estimated $7.2 billion in added net interest income over 12 months. Although we're unlikely to see a 100-basis-point shift in 12 months, we are on the verge of seeing higher interest rates significantly bolster BofA's profit potential.\nThe other impressive aspect of Warren Buffett's second-largest holding is its digitization efforts. Though you probably don't think of Bank of America as a tech-savvy business, the number of digital active users has grown to nearly 41 million, with 43% of all sales in the third quarter coming from online or mobile banking. This push to digitize has allowed the company to consolidate some of its branches in order to reduce costs.\nBank of America should be a no-brainer buy as it enters the sweet spot of its growth cycle.","news_type":1},"isVote":1,"tweetType":1,"viewCount":459,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":877429084,"gmtCreate":1637974465738,"gmtModify":1637974465789,"author":{"id":"4092740792654610","authorId":"4092740792654610","name":"Winalot","avatar":"https://static.tigerbbs.com/8b310145827ffdca4a18cd3a698ce65e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Good for vaccine manufacturers but bad for mankind","listText":"Good for vaccine manufacturers but bad for mankind","text":"Good for vaccine manufacturers but bad for mankind","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/877429084","repostId":"1125886564","repostType":2,"repost":{"id":"1125886564","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1637938179,"share":"https://www.laohu8.com/m/news/1125886564?lang=&edition=full","pubTime":"2021-11-26 22:49","market":"us","language":"en","title":"Vaccine stocks continued to rise in early trading, Moderna shares surged more than 23%.","url":"https://stock-news.laohu8.com/highlight/detail?id=1125886564","media":"Tiger Newspress","summary":"Vaccine stocks continued to rise in early trading, Moderna shares surged more than 23% and BioNTech ","content":"<p>Vaccine stocks continued to rise in early trading, Moderna shares surged more than 23% and BioNTech jumped nearly 19%.<img src=\"https://static.tigerbbs.com/2e9f40662925ec57d0176cf5f1e36df4\" tg-width=\"876\" tg-height=\"613\" referrerpolicy=\"no-referrer\">Germany's BioNTech said it is studying the effectiveness of its COVID-19 vaccine against the new B.1.1.529 variant detected in South Africa - The Economic Times.</p>\n<p>\"We expect more data from the laboratory tests in two weeks at the latest. These data will provide more information about whether B.1.1.529 could be an escape variant that may require an adjustment of our vaccine if the variant spreads globally,\" a BioNTech spokesperson said.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaccine stocks continued to rise in early trading, Moderna shares surged more than 23%.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaccine stocks continued to rise in early trading, Moderna shares surged more than 23%.\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-26 22:49</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Vaccine stocks continued to rise in early trading, Moderna shares surged more than 23% and BioNTech jumped nearly 19%.<img src=\"https://static.tigerbbs.com/2e9f40662925ec57d0176cf5f1e36df4\" tg-width=\"876\" tg-height=\"613\" referrerpolicy=\"no-referrer\">Germany's BioNTech said it is studying the effectiveness of its COVID-19 vaccine against the new B.1.1.529 variant detected in South Africa - The Economic Times.</p>\n<p>\"We expect more data from the laboratory tests in two weeks at the latest. These data will provide more information about whether B.1.1.529 could be an escape variant that may require an adjustment of our vaccine if the variant spreads globally,\" a BioNTech spokesperson said.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1125886564","content_text":"Vaccine stocks continued to rise in early trading, Moderna shares surged more than 23% and BioNTech jumped nearly 19%.Germany's BioNTech said it is studying the effectiveness of its COVID-19 vaccine against the new B.1.1.529 variant detected in South Africa - The Economic Times.\n\"We expect more data from the laboratory tests in two weeks at the latest. These data will provide more information about whether B.1.1.529 could be an escape variant that may require an adjustment of our vaccine if the variant spreads globally,\" a BioNTech spokesperson said.","news_type":1},"isVote":1,"tweetType":1,"viewCount":444,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":873254971,"gmtCreate":1636951799875,"gmtModify":1636951799875,"author":{"id":"4092740792654610","authorId":"4092740792654610","name":"Winalot","avatar":"https://static.tigerbbs.com/8b310145827ffdca4a18cd3a698ce65e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Nice for cohu ","listText":"Nice for cohu ","text":"Nice for cohu","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/873254971","repostId":"2183464920","repostType":2,"repost":{"id":"2183464920","pubTimestamp":1636944360,"share":"https://www.laohu8.com/m/news/2183464920?lang=&edition=full","pubTime":"2021-11-15 10:46","market":"us","language":"en","title":"Prediction: These Will Be 2 of the Strongest Stocks in 2022","url":"https://stock-news.laohu8.com/highlight/detail?id=2183464920","media":"Motley Fool","summary":"With the new year right around the corner, it could be the perfect time to consider some explosive new opportunities.","content":"<p>As the present year draws to a close, many investors might be thinking about the moves they should make in 2022. But with the broad <b>S&P 500</b> index near all-time highs, the prospect of opening new positions can be daunting given that many popular stocks are looking quite expensive.</p>\n<p>If you're willing to venture off the beaten path, some pockets of the market are still attractively priced, though.</p>\n<p><b>Cohu</b> (NASDAQ:COHU) is a semiconductor service company that Wall Street thinks could almost double from here, and action-camera company <b><a href=\"https://laohu8.com/S/GPRO\">GoPro</a></b> (NASDAQ:GPRO) has just delivered consecutive blockbuster quarterly results, spurring an analyst upgrade from well-respected investment bank <b><a href=\"https://laohu8.com/S/MSTLW\">Morgan Stanley</a></b> this week.</p>\n<p>These two stocks are just getting warmed up, and here's why they could be big-time contributors to your portfolio next year.</p>\n<h2>The case for Cohu</h2>\n<p>Cohu supplies testing and handling equipment to the world's largest semiconductor producers, designed to speed up the manufacturing process of fragile and highly valuable computer chips.</p>\n<p>A crippling semiconductor shortage has raged throughout 2020 and 2021, triggered by pandemic-related production shutdowns across Asia. These advanced computer chips are critical to most digital consumer goods, from mobile devices all the way up to new cars, and the inability to access them has caused a price surge in many of these products.</p>\n<p>The new vehicle market was arguably the most impacted sector, with some dealerships reporting an 80% decline in their inventories. As a result, the price of a new car is up almost 10% in the last 12 months, and the price of a used car is up a whopping 26% as consumers settle for pre-owned models instead.</p>\n<p>Cohu is playing a crucial role in alleviating these issues by focusing on the automotive segment, which is now its largest, accounting for 18% of total revenue. Its Neon inspection system is designed to detect defects in some of the world's smallest automotive-related semiconductors while still handling them at high speeds to prevent manufacturing delays.</p>\n<p>This equipment is in high demand from semiconductor producers who need to quickly expand capacity to clear backlogs, and as such, Cohu is having its most profitable year since 2017. It's set to grow revenue by 39% compared to 2020, with $3.01 in earnings per share.</p>\n<p>Based on its current share price of $36, it trades at a forward price-to-earnings multiple of just 12, about 65% cheaper than the broad <b><a href=\"https://laohu8.com/S/EEME\">iShares</a> Semiconductor ETF</b>, which trades at a multiple of 35. It's therefore within the realm of probability that the stock could double from here -- yet even if it did, it would <i>still </i>be cheaper than its peers in the industry.</p>\n<h2>The case for GoPro</h2>\n<p>Action camera leader GoPro is a corporate comeback story for the ages. Its stock fell 97% between its public listing in 2014 and the 2020 pandemic, yet it has been resurrected by a strong performance from its management team. They've pivoted the company away from a <a href=\"https://laohu8.com/S/AONE.U\">one</a>-dimensional revenue stream, and set up a booming subscription business with extremely high profit margins.</p>\n<p>GoPro's new HERO10 Black camera shoots video in 5.2K high definition at a price point of just $499 -- its most comparable competitor, according to the company, is priced at $3,500. Traditionally, GoPro has sold its cameras through some of the largest retailers in the world, but it's currently shifting to a more direct-to-consumer model using its GoPro.com website. It means higher gross margins for the company, as it now keeps the retailers' cut.</p>\n<p>But perhaps more notably is the new GoPro.com subscription. For $49.99 per year, brand loyalists can access exclusive product discounts, unlimited cloud storage, live streaming, and damaged product replacements. The growth in subscriptions has been astronomical.</p>\n<table>\n <thead>\n <tr>\n <th><p>Metric</p></th>\n <th><p>Q3 2019</p></th>\n <th><p>Q3 2020</p></th>\n <th><p>Q3 2021</p></th>\n <th><p>CAGR</p></th>\n </tr>\n </thead>\n <tbody>\n <tr>\n <td><p>Subscriptions</p></td>\n <td><p>305,000</p></td>\n <td><p>501,000</p></td>\n <td><p>1,340,000</p></td>\n <td><p>109%</p></td>\n </tr>\n </tbody>\n</table>\n<p>Data source: GoPro. CAGR = compound annual growth rate.</p>\n<p>The company expects to enter 2022 with 1.7 million paying subscribers, which will generate $90 million in revenue in the new year. But the kicker is the 70% to 80% gross margins -- this is an <i>incredibly </i>profitable business segment, and with its rapid growth will likely make an impactful contribution to GoPro's earnings.</p>\n<p>Analysts expect the company to deliver $0.83 in earnings per share for 2021, which places the stock at a forward price-to-earnings multiple of 12 times. But with Wall Street titans like Morgan Stanley getting behind the company through a rating upgrade, investors could be enticed to ascribe a valuation that's more aligned with the broader <b>Nasdaq 100</b> next year, which trades at an earnings multiple of 36.</p>\n<p>GoPro is certainly generating the growth to back that up and might be set to deliver top-tier returns in 2022.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Prediction: These Will Be 2 of the Strongest Stocks in 2022</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPrediction: These Will Be 2 of the Strongest Stocks in 2022\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-15 10:46 GMT+8 <a href=https://www.fool.com/investing/2021/11/14/prediction-2-of-the-strongest-stocks-in-2022/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>As the present year draws to a close, many investors might be thinking about the moves they should make in 2022. But with the broad S&P 500 index near all-time highs, the prospect of opening new ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/11/14/prediction-2-of-the-strongest-stocks-in-2022/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"COHU":"科休半导体","GPRO":"GoPro"},"source_url":"https://www.fool.com/investing/2021/11/14/prediction-2-of-the-strongest-stocks-in-2022/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2183464920","content_text":"As the present year draws to a close, many investors might be thinking about the moves they should make in 2022. But with the broad S&P 500 index near all-time highs, the prospect of opening new positions can be daunting given that many popular stocks are looking quite expensive.\nIf you're willing to venture off the beaten path, some pockets of the market are still attractively priced, though.\nCohu (NASDAQ:COHU) is a semiconductor service company that Wall Street thinks could almost double from here, and action-camera company GoPro (NASDAQ:GPRO) has just delivered consecutive blockbuster quarterly results, spurring an analyst upgrade from well-respected investment bank Morgan Stanley this week.\nThese two stocks are just getting warmed up, and here's why they could be big-time contributors to your portfolio next year.\nThe case for Cohu\nCohu supplies testing and handling equipment to the world's largest semiconductor producers, designed to speed up the manufacturing process of fragile and highly valuable computer chips.\nA crippling semiconductor shortage has raged throughout 2020 and 2021, triggered by pandemic-related production shutdowns across Asia. These advanced computer chips are critical to most digital consumer goods, from mobile devices all the way up to new cars, and the inability to access them has caused a price surge in many of these products.\nThe new vehicle market was arguably the most impacted sector, with some dealerships reporting an 80% decline in their inventories. As a result, the price of a new car is up almost 10% in the last 12 months, and the price of a used car is up a whopping 26% as consumers settle for pre-owned models instead.\nCohu is playing a crucial role in alleviating these issues by focusing on the automotive segment, which is now its largest, accounting for 18% of total revenue. Its Neon inspection system is designed to detect defects in some of the world's smallest automotive-related semiconductors while still handling them at high speeds to prevent manufacturing delays.\nThis equipment is in high demand from semiconductor producers who need to quickly expand capacity to clear backlogs, and as such, Cohu is having its most profitable year since 2017. It's set to grow revenue by 39% compared to 2020, with $3.01 in earnings per share.\nBased on its current share price of $36, it trades at a forward price-to-earnings multiple of just 12, about 65% cheaper than the broad iShares Semiconductor ETF, which trades at a multiple of 35. It's therefore within the realm of probability that the stock could double from here -- yet even if it did, it would still be cheaper than its peers in the industry.\nThe case for GoPro\nAction camera leader GoPro is a corporate comeback story for the ages. Its stock fell 97% between its public listing in 2014 and the 2020 pandemic, yet it has been resurrected by a strong performance from its management team. They've pivoted the company away from a one-dimensional revenue stream, and set up a booming subscription business with extremely high profit margins.\nGoPro's new HERO10 Black camera shoots video in 5.2K high definition at a price point of just $499 -- its most comparable competitor, according to the company, is priced at $3,500. Traditionally, GoPro has sold its cameras through some of the largest retailers in the world, but it's currently shifting to a more direct-to-consumer model using its GoPro.com website. It means higher gross margins for the company, as it now keeps the retailers' cut.\nBut perhaps more notably is the new GoPro.com subscription. For $49.99 per year, brand loyalists can access exclusive product discounts, unlimited cloud storage, live streaming, and damaged product replacements. The growth in subscriptions has been astronomical.\n\n\n\nMetric\nQ3 2019\nQ3 2020\nQ3 2021\nCAGR\n\n\n\n\nSubscriptions\n305,000\n501,000\n1,340,000\n109%\n\n\n\nData source: GoPro. CAGR = compound annual growth rate.\nThe company expects to enter 2022 with 1.7 million paying subscribers, which will generate $90 million in revenue in the new year. But the kicker is the 70% to 80% gross margins -- this is an incredibly profitable business segment, and with its rapid growth will likely make an impactful contribution to GoPro's earnings.\nAnalysts expect the company to deliver $0.83 in earnings per share for 2021, which places the stock at a forward price-to-earnings multiple of 12 times. But with Wall Street titans like Morgan Stanley getting behind the company through a rating upgrade, investors could be enticed to ascribe a valuation that's more aligned with the broader Nasdaq 100 next year, which trades at an earnings multiple of 36.\nGoPro is certainly generating the growth to back that up and might be set to deliver top-tier returns in 2022.","news_type":1},"isVote":1,"tweetType":1,"viewCount":401,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":821345744,"gmtCreate":1633701945854,"gmtModify":1633701945967,"author":{"id":"4092740792654610","authorId":"4092740792654610","name":"Winalot","avatar":"https://static.tigerbbs.com/8b310145827ffdca4a18cd3a698ce65e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Come come come. More good news please","listText":"Come come come. More good news please","text":"Come come come. More good news please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/821345744","repostId":"1198728824","repostType":4,"repost":{"id":"1198728824","pubTimestamp":1633699239,"share":"https://www.laohu8.com/m/news/1198728824?lang=&edition=full","pubTime":"2021-10-08 21:20","market":"us","language":"en","title":"Novavax inks $372M deal with Mabion for COVID-19 vaccine manufacturing","url":"https://stock-news.laohu8.com/highlight/detail?id=1198728824","media":"seekingalpha","summary":"Novavax is trading ~1% higher in the pre-market after Polish biotech firm Mabion SA said it signed a","content":"<p>Novavax is trading ~1% higher in the pre-market after Polish biotech firm Mabion SA said it signed a $372 million worth deal with the company on Oct. 08 for its experimental COVID-19 vaccine.</p>\n<p><img src=\"https://static.tigerbbs.com/4edc5f6f3230139f31f3c711942e1550\" tg-width=\"1185\" tg-height=\"577\" width=\"100%\" height=\"auto\"></p>\n<p>Per the terms, Mabion is expected to produce a COVID-19 vaccine candidate antigen under the name NVX-CoV2373 beginning Dec. 2021 in compliance with the GMP standard. The commercial manufacturing agreement will run from 2022 to 2025 with an option for extension.</p>\n<p>Previously, Novavax(NASDAQ:NVAX)delayed the production and regulatory timeline for its protein-based vaccine candidate named NVX-CoV2373.</p>\n<p>However, it has generated promising results in a large Phase 3 clinical trial indicating 100% protection against moderate and severe COVID-19 with ~90% overall efficacy.</p>\n<p>Novavax (NVAX) shares surged in September when the company announced the regulatory submission to the World Health Organization (WHO) seeking an emergency use listing (EUL) for the vaccine candidate.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax inks $372M deal with Mabion for COVID-19 vaccine manufacturing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax inks $372M deal with Mabion for COVID-19 vaccine manufacturing\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-08 21:20 GMT+8 <a href=https://seekingalpha.com/news/3750902-novavax-partners-with-mabion-for-covid-19-vaccine-manufacturing><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Novavax is trading ~1% higher in the pre-market after Polish biotech firm Mabion SA said it signed a $372 million worth deal with the company on Oct. 08 for its experimental COVID-19 vaccine.\n\nPer the...</p>\n\n<a href=\"https://seekingalpha.com/news/3750902-novavax-partners-with-mabion-for-covid-19-vaccine-manufacturing\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://seekingalpha.com/news/3750902-novavax-partners-with-mabion-for-covid-19-vaccine-manufacturing","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1198728824","content_text":"Novavax is trading ~1% higher in the pre-market after Polish biotech firm Mabion SA said it signed a $372 million worth deal with the company on Oct. 08 for its experimental COVID-19 vaccine.\n\nPer the terms, Mabion is expected to produce a COVID-19 vaccine candidate antigen under the name NVX-CoV2373 beginning Dec. 2021 in compliance with the GMP standard. The commercial manufacturing agreement will run from 2022 to 2025 with an option for extension.\nPreviously, Novavax(NASDAQ:NVAX)delayed the production and regulatory timeline for its protein-based vaccine candidate named NVX-CoV2373.\nHowever, it has generated promising results in a large Phase 3 clinical trial indicating 100% protection against moderate and severe COVID-19 with ~90% overall efficacy.\nNovavax (NVAX) shares surged in September when the company announced the regulatory submission to the World Health Organization (WHO) seeking an emergency use listing (EUL) for the vaccine candidate.","news_type":1},"isVote":1,"tweetType":1,"viewCount":564,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":862698160,"gmtCreate":1632873908975,"gmtModify":1632873908975,"author":{"id":"4092740792654610","authorId":"4092740792654610","name":"Winalot","avatar":"https://static.tigerbbs.com/8b310145827ffdca4a18cd3a698ce65e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Time to pick up stocks","listText":"Time to pick up stocks","text":"Time to pick up stocks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/862698160","repostId":"1172071780","repostType":4,"isVote":1,"tweetType":1,"viewCount":375,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":873254971,"gmtCreate":1636951799875,"gmtModify":1636951799875,"author":{"id":"4092740792654610","authorId":"4092740792654610","name":"Winalot","avatar":"https://static.tigerbbs.com/8b310145827ffdca4a18cd3a698ce65e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Nice for cohu ","listText":"Nice for cohu ","text":"Nice for cohu","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/873254971","repostId":"2183464920","repostType":2,"isVote":1,"tweetType":1,"viewCount":401,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":608749282,"gmtCreate":1638795158663,"gmtModify":1638795950059,"author":{"id":"4092740792654610","authorId":"4092740792654610","name":"Winalot","avatar":"https://static.tigerbbs.com/8b310145827ffdca4a18cd3a698ce65e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Meta is the new ","listText":"Meta is the new ","text":"Meta is the new","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/608749282","repostId":"2189186504","repostType":4,"isVote":1,"tweetType":1,"viewCount":296,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":877429084,"gmtCreate":1637974465738,"gmtModify":1637974465789,"author":{"id":"4092740792654610","authorId":"4092740792654610","name":"Winalot","avatar":"https://static.tigerbbs.com/8b310145827ffdca4a18cd3a698ce65e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Good for vaccine manufacturers but bad for mankind","listText":"Good for vaccine manufacturers but bad for mankind","text":"Good for vaccine manufacturers but bad for mankind","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/877429084","repostId":"1125886564","repostType":2,"repost":{"id":"1125886564","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1637938179,"share":"https://www.laohu8.com/m/news/1125886564?lang=&edition=full","pubTime":"2021-11-26 22:49","market":"us","language":"en","title":"Vaccine stocks continued to rise in early trading, Moderna shares surged more than 23%.","url":"https://stock-news.laohu8.com/highlight/detail?id=1125886564","media":"Tiger Newspress","summary":"Vaccine stocks continued to rise in early trading, Moderna shares surged more than 23% and BioNTech ","content":"<p>Vaccine stocks continued to rise in early trading, Moderna shares surged more than 23% and BioNTech jumped nearly 19%.<img src=\"https://static.tigerbbs.com/2e9f40662925ec57d0176cf5f1e36df4\" tg-width=\"876\" tg-height=\"613\" referrerpolicy=\"no-referrer\">Germany's BioNTech said it is studying the effectiveness of its COVID-19 vaccine against the new B.1.1.529 variant detected in South Africa - The Economic Times.</p>\n<p>\"We expect more data from the laboratory tests in two weeks at the latest. These data will provide more information about whether B.1.1.529 could be an escape variant that may require an adjustment of our vaccine if the variant spreads globally,\" a BioNTech spokesperson said.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaccine stocks continued to rise in early trading, Moderna shares surged more than 23%.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaccine stocks continued to rise in early trading, Moderna shares surged more than 23%.\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-26 22:49</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Vaccine stocks continued to rise in early trading, Moderna shares surged more than 23% and BioNTech jumped nearly 19%.<img src=\"https://static.tigerbbs.com/2e9f40662925ec57d0176cf5f1e36df4\" tg-width=\"876\" tg-height=\"613\" referrerpolicy=\"no-referrer\">Germany's BioNTech said it is studying the effectiveness of its COVID-19 vaccine against the new B.1.1.529 variant detected in South Africa - The Economic Times.</p>\n<p>\"We expect more data from the laboratory tests in two weeks at the latest. These data will provide more information about whether B.1.1.529 could be an escape variant that may require an adjustment of our vaccine if the variant spreads globally,\" a BioNTech spokesperson said.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1125886564","content_text":"Vaccine stocks continued to rise in early trading, Moderna shares surged more than 23% and BioNTech jumped nearly 19%.Germany's BioNTech said it is studying the effectiveness of its COVID-19 vaccine against the new B.1.1.529 variant detected in South Africa - The Economic Times.\n\"We expect more data from the laboratory tests in two weeks at the latest. These data will provide more information about whether B.1.1.529 could be an escape variant that may require an adjustment of our vaccine if the variant spreads globally,\" a BioNTech spokesperson said.","news_type":1},"isVote":1,"tweetType":1,"viewCount":444,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":862698160,"gmtCreate":1632873908975,"gmtModify":1632873908975,"author":{"id":"4092740792654610","authorId":"4092740792654610","name":"Winalot","avatar":"https://static.tigerbbs.com/8b310145827ffdca4a18cd3a698ce65e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Time to pick up stocks","listText":"Time to pick up stocks","text":"Time to pick up stocks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/862698160","repostId":"1172071780","repostType":4,"isVote":1,"tweetType":1,"viewCount":375,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":601772943,"gmtCreate":1638577213231,"gmtModify":1638577213231,"author":{"id":"4092740792654610","authorId":"4092740792654610","name":"Winalot","avatar":"https://static.tigerbbs.com/8b310145827ffdca4a18cd3a698ce65e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/601772943","repostId":"2188528084","repostType":4,"repost":{"id":"2188528084","pubTimestamp":1638543717,"share":"https://www.laohu8.com/m/news/2188528084?lang=&edition=full","pubTime":"2021-12-03 23:01","market":"us","language":"en","title":"5 Warren Buffett Stocks Are Screaming Buys in December","url":"https://stock-news.laohu8.com/highlight/detail?id=2188528084","media":"Motley Fool","summary":"Riding the Oracle of Omaha's coattails is often a moneymaking proposition.","content":"<p>Making money for shareholders has been in Warren Buffett's blood since taking over as CEO of <b>Berkshire Hathaway</b> (NYSE:BRK.A)(NYSE:BRK.B) in 1965. Over that time, he's led Berkshire to an average annual gain of about 20%, which translates into aggregate gains, including the year-to-date performance of the Class A shares (BRK.A), of approximately 3,500,000%. Gains like this are why the investing world pays close attention to what the Oracle of Omaha is buying and selling.</p>\n<p>Based on the latest 13F filing with the Securities and Exchange Commission, Berkshire Hathaway has stakes in 45 securities. Among these 45 holdings, five Warren Buffett stocks stand out as screaming buys in December.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/e92116e97f06291ec28eda85974acb1b\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Berkshire Hathaway CEO Warren Buffett. Image source: The Motley Fool.</span></p>\n<h2>Amazon</h2>\n<p>While I'm well aware this isn't going to win any points for originality, e-commerce kingpin <b>Amazon</b> (NASDAQ:AMZN) remains a surefire stock to own in Buffett's portfolio.</p>\n<p>Most people are familiar with Amazon for its dominant online marketplace. According to an August report from eMarketer, Amazon is expected to handle 41.4% of all U.S. online sales in 2021. That's about 34 percentage points higher than the next-closest competitor. The key, though, is that the company has signed up 200 million people to a Prime membership worldwide. The annual fees collected from these members helps to buoy razor-thin retail margins and allows Amazon to consistently undercut brick-and-mortar retailers on price.</p>\n<p>However, the company's future rests with its considerably higher-margin segments, such as cloud infrastructure services. Amazon Web Services (AWS) accounted for only 13.4% of net sales in the third quarter, yet contributed 61.8% of the company's operating income. Even with online sales slowing as coronavirus vaccination rates tick higher and life returns to some semblance of normal, Amazon's critical highest-margin segments (AWS, subscriptions, and advertising) continue to grow rapidly.</p>\n<p>If Amazon were to simply hit the median price-to-operating cash flow it's been trading at for the past 11 years, we could be looking at a $10,000 a share company by mid-decade.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/b18b49b2b35da2fc49e0a83b883d1c22\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Bristol Myers Squibb</h2>\n<p>Another Warren Buffett stock that's quickly become a screaming buy is pharmaceutical company <b>Bristol Myers Squibb</b> (NYSE:BMY).</p>\n<p>Bristol Myers' success is dependent on organically developing and growing its brand-name pharmaceutical portfolio, as well as leaning on acquisitions to push the needle higher.</p>\n<p>From an internal development perspective, some of the company's biggest wins include cancer immunotherapy Opdivo and oral anticoagulant Eliquis -- the latter of which was developed with <b>Pfizer</b>. Eliquis should push for $10 billion in sales for Bristol Myers this year, while Opdivo hit $7 billion in revenue last year. Opdivo is particularly intriguing given that it's being examined in dozens of clinical trials and has already received approval for 10 indications in the U.S. Label expansion opportunities, pricing power, and improved cancer screening diagnostics all have the potential to make this a $10 billion a year therapy.</p>\n<p>Bristol Myers also made waves with its November 2019 acquisition of cancer and immunology drugmaker Celgene. Buying Celgene added a handful of blockbuster drugs to Bristol's portfolio, including multiple myeloma treatment Revlimid, which will potentially top $13 billion in 2021 sales. Revlimid is protected from an onslaught of generic competition for four more years, which means Bristol Myers will be generating bountiful cash flow in the meantime.</p>\n<p>At just 7 times consensus forward-year earnings per share, it's an absolute steal.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/a295212aa2b7c99c921b8afa2a4aa3a2\" tg-width=\"700\" tg-height=\"467\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2><a href=\"https://laohu8.com/S/V\">Visa</a></h2>\n<p>The recent sell-off in payment processing behemoth <b>Visa</b> (NYSE:V) makes it a screaming buy, too.</p>\n<p>Over the past couple of months, Wall Street and investors have raised concerns about payment facilitators like <b>Square</b> or cryptocurrencies eating into Visa's dominance. However, these concerns seem unfounded given Visa's utter dominance of the processing space. As of 2018, it held a 53% share of U.S. credit card network purchase volume, which was more than 30 percentage points higher than the next-closest competitor. I should also mention the U.S. is the leading market for consumption in the world.</p>\n<p>Visa's outperformance is also a function of its lending avoidance. By sticking to the processing side of the equation, the company avoids having to set aside capital to cover credit delinquencies during recessions. Not having to cover credit/loan losses is a big reason why Visa rebounds faster than other financial stocks and maintains a profit margin north of 50%.</p>\n<p>And have I mentioned that Visa is <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the smartest ways to play rapidly rising inflation? Since the company's fees are tied to the price of goods and services, its revenue and profits will grow as the price for goods and services rises.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1c5a0257bdd17a5ff3cf22a10de43ce0\" tg-width=\"700\" tg-height=\"467\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Teva Pharmaceutical Industries</h2>\n<p>The cheapest stock in Warren Buffett's portfolio, brand-name and generic-drug company <b>Teva Pharmaceutical Industries</b> (NYSE:TEVA), is begging to be bought as well. Teva can currently be purchased for a little more than 3 times Wall Street's consensus earnings per share in 2021 and 2022.</p>\n<p>Unlike Amazon, Bristol Myers, and Visa, Teva hasn't been firing on all cylinders. Since 2016, the company settled a bribery scandal, buried itself in debt after overpaying for generic-drugmaker Actavis, and has faced a mountain of litigation concerning its role in the opioid epidemic. But while there's reason to not give Teva a valuation premium, an earnings multiple of 3 is overly pessimistic given the steps being taken to right the ship.</p>\n<p>In late 2017, Kare Schultz took over as CEO. He's a turnaround specialist who's taken clear steps to improve the business. During his tenure, net debt has been reduced from over $34 billion to around $22 billion, and annual operating expenses have been cut by a double-digit percentage. Teva is leaner than it's been in years and is capable of maintaining annual operating cash flow of $2 billion (or higher).</p>\n<p>Furthermore, there's light at the end of the tunnel when it comes to opioid litigation. A trial in California recently went in favor of drugmakers, which could put some bargaining power back in Teva's court. If Schultz can negotiate a national settlement where free or reduced-cost medicine, not cash, is the lure, Teva could probably double very quickly.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/7343c3ce7330b86321a8ec9384d4baea\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Bank of America</h2>\n<p>The final Warren Buffett stock to buy hand over fist in December is banking juggernaut <b>Bank of America</b> (NYSE:BAC).</p>\n<p>Bank stocks like BofA are on the cusp of hitting their growth sweet spot. With inflation picking up, the Federal Reserve will more than likely need to act in 2022 or 2023 to raise interest rates. Boosting the federal funds target rate will lift the net interest income-earning potential of banks with outstanding variable-rate loans.</p>\n<p>Among money-center banks, none is more interest-sensitive than Bank of America. The company's third-quarter earnings presentation points out that a 100-basis-point parallel shift in the interest rate yield curve would generate an estimated $7.2 billion in added net interest income over 12 months. Although we're unlikely to see a 100-basis-point shift in 12 months, we are on the verge of seeing higher interest rates significantly bolster BofA's profit potential.</p>\n<p>The other impressive aspect of Warren Buffett's second-largest holding is its digitization efforts. Though you probably don't think of Bank of America as a tech-savvy business, the number of digital active users has grown to nearly 41 million, with 43% of all sales in the third quarter coming from online or mobile banking. This push to digitize has allowed the company to consolidate some of its branches in order to reduce costs.</p>\n<p>Bank of America should be a no-brainer buy as it enters the sweet spot of its growth cycle.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Warren Buffett Stocks Are Screaming Buys in December</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Warren Buffett Stocks Are Screaming Buys in December\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-03 23:01 GMT+8 <a href=https://www.fool.com/investing/2021/12/03/5-warren-buffett-stocks-screaming-buys-in-december/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Making money for shareholders has been in Warren Buffett's blood since taking over as CEO of Berkshire Hathaway (NYSE:BRK.A)(NYSE:BRK.B) in 1965. Over that time, he's led Berkshire to an average ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/03/5-warren-buffett-stocks-screaming-buys-in-december/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4504":"桥水持仓","TEVA":"梯瓦制药","BK4548":"巴美列捷福持仓","V":"Visa","BK4176":"多领域控股","BK4532":"文艺复兴科技持仓","BK4554":"元宇宙及AR概念","BK4106":"数据处理与外包服务","BK4553":"喜马拉雅资本持仓","BRK.A":"伯克希尔","BK4534":"瑞士信贷持仓","BK4507":"流媒体概念","BRK.B":"伯克希尔B","BAC":"美国银行","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","BK4566":"资本集团","BMY":"施贵宝","BK4557":"大麻股","BK4524":"宅经济概念","BK4535":"淡马锡持仓","BK4559":"巴菲特持仓","BK4527":"明星科技股","BK4538":"云计算","BK4550":"红杉资本持仓","AMZN":"亚马逊","BK4122":"互联网与直销零售","BK4503":"景林资产持仓","BK4551":"寇图资本持仓","BK4207":"综合性银行","BK4561":"索罗斯持仓"},"source_url":"https://www.fool.com/investing/2021/12/03/5-warren-buffett-stocks-screaming-buys-in-december/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2188528084","content_text":"Making money for shareholders has been in Warren Buffett's blood since taking over as CEO of Berkshire Hathaway (NYSE:BRK.A)(NYSE:BRK.B) in 1965. Over that time, he's led Berkshire to an average annual gain of about 20%, which translates into aggregate gains, including the year-to-date performance of the Class A shares (BRK.A), of approximately 3,500,000%. Gains like this are why the investing world pays close attention to what the Oracle of Omaha is buying and selling.\nBased on the latest 13F filing with the Securities and Exchange Commission, Berkshire Hathaway has stakes in 45 securities. Among these 45 holdings, five Warren Buffett stocks stand out as screaming buys in December.\nBerkshire Hathaway CEO Warren Buffett. Image source: The Motley Fool.\nAmazon\nWhile I'm well aware this isn't going to win any points for originality, e-commerce kingpin Amazon (NASDAQ:AMZN) remains a surefire stock to own in Buffett's portfolio.\nMost people are familiar with Amazon for its dominant online marketplace. According to an August report from eMarketer, Amazon is expected to handle 41.4% of all U.S. online sales in 2021. That's about 34 percentage points higher than the next-closest competitor. The key, though, is that the company has signed up 200 million people to a Prime membership worldwide. The annual fees collected from these members helps to buoy razor-thin retail margins and allows Amazon to consistently undercut brick-and-mortar retailers on price.\nHowever, the company's future rests with its considerably higher-margin segments, such as cloud infrastructure services. Amazon Web Services (AWS) accounted for only 13.4% of net sales in the third quarter, yet contributed 61.8% of the company's operating income. Even with online sales slowing as coronavirus vaccination rates tick higher and life returns to some semblance of normal, Amazon's critical highest-margin segments (AWS, subscriptions, and advertising) continue to grow rapidly.\nIf Amazon were to simply hit the median price-to-operating cash flow it's been trading at for the past 11 years, we could be looking at a $10,000 a share company by mid-decade.\nImage source: Getty Images.\nBristol Myers Squibb\nAnother Warren Buffett stock that's quickly become a screaming buy is pharmaceutical company Bristol Myers Squibb (NYSE:BMY).\nBristol Myers' success is dependent on organically developing and growing its brand-name pharmaceutical portfolio, as well as leaning on acquisitions to push the needle higher.\nFrom an internal development perspective, some of the company's biggest wins include cancer immunotherapy Opdivo and oral anticoagulant Eliquis -- the latter of which was developed with Pfizer. Eliquis should push for $10 billion in sales for Bristol Myers this year, while Opdivo hit $7 billion in revenue last year. Opdivo is particularly intriguing given that it's being examined in dozens of clinical trials and has already received approval for 10 indications in the U.S. Label expansion opportunities, pricing power, and improved cancer screening diagnostics all have the potential to make this a $10 billion a year therapy.\nBristol Myers also made waves with its November 2019 acquisition of cancer and immunology drugmaker Celgene. Buying Celgene added a handful of blockbuster drugs to Bristol's portfolio, including multiple myeloma treatment Revlimid, which will potentially top $13 billion in 2021 sales. Revlimid is protected from an onslaught of generic competition for four more years, which means Bristol Myers will be generating bountiful cash flow in the meantime.\nAt just 7 times consensus forward-year earnings per share, it's an absolute steal.\nImage source: Getty Images.\nVisa\nThe recent sell-off in payment processing behemoth Visa (NYSE:V) makes it a screaming buy, too.\nOver the past couple of months, Wall Street and investors have raised concerns about payment facilitators like Square or cryptocurrencies eating into Visa's dominance. However, these concerns seem unfounded given Visa's utter dominance of the processing space. As of 2018, it held a 53% share of U.S. credit card network purchase volume, which was more than 30 percentage points higher than the next-closest competitor. I should also mention the U.S. is the leading market for consumption in the world.\nVisa's outperformance is also a function of its lending avoidance. By sticking to the processing side of the equation, the company avoids having to set aside capital to cover credit delinquencies during recessions. Not having to cover credit/loan losses is a big reason why Visa rebounds faster than other financial stocks and maintains a profit margin north of 50%.\nAnd have I mentioned that Visa is one of the smartest ways to play rapidly rising inflation? Since the company's fees are tied to the price of goods and services, its revenue and profits will grow as the price for goods and services rises.\nImage source: Getty Images.\nTeva Pharmaceutical Industries\nThe cheapest stock in Warren Buffett's portfolio, brand-name and generic-drug company Teva Pharmaceutical Industries (NYSE:TEVA), is begging to be bought as well. Teva can currently be purchased for a little more than 3 times Wall Street's consensus earnings per share in 2021 and 2022.\nUnlike Amazon, Bristol Myers, and Visa, Teva hasn't been firing on all cylinders. Since 2016, the company settled a bribery scandal, buried itself in debt after overpaying for generic-drugmaker Actavis, and has faced a mountain of litigation concerning its role in the opioid epidemic. But while there's reason to not give Teva a valuation premium, an earnings multiple of 3 is overly pessimistic given the steps being taken to right the ship.\nIn late 2017, Kare Schultz took over as CEO. He's a turnaround specialist who's taken clear steps to improve the business. During his tenure, net debt has been reduced from over $34 billion to around $22 billion, and annual operating expenses have been cut by a double-digit percentage. Teva is leaner than it's been in years and is capable of maintaining annual operating cash flow of $2 billion (or higher).\nFurthermore, there's light at the end of the tunnel when it comes to opioid litigation. A trial in California recently went in favor of drugmakers, which could put some bargaining power back in Teva's court. If Schultz can negotiate a national settlement where free or reduced-cost medicine, not cash, is the lure, Teva could probably double very quickly.\nImage source: Getty Images.\nBank of America\nThe final Warren Buffett stock to buy hand over fist in December is banking juggernaut Bank of America (NYSE:BAC).\nBank stocks like BofA are on the cusp of hitting their growth sweet spot. With inflation picking up, the Federal Reserve will more than likely need to act in 2022 or 2023 to raise interest rates. Boosting the federal funds target rate will lift the net interest income-earning potential of banks with outstanding variable-rate loans.\nAmong money-center banks, none is more interest-sensitive than Bank of America. The company's third-quarter earnings presentation points out that a 100-basis-point parallel shift in the interest rate yield curve would generate an estimated $7.2 billion in added net interest income over 12 months. Although we're unlikely to see a 100-basis-point shift in 12 months, we are on the verge of seeing higher interest rates significantly bolster BofA's profit potential.\nThe other impressive aspect of Warren Buffett's second-largest holding is its digitization efforts. Though you probably don't think of Bank of America as a tech-savvy business, the number of digital active users has grown to nearly 41 million, with 43% of all sales in the third quarter coming from online or mobile banking. This push to digitize has allowed the company to consolidate some of its branches in order to reduce costs.\nBank of America should be a no-brainer buy as it enters the sweet spot of its growth cycle.","news_type":1},"isVote":1,"tweetType":1,"viewCount":459,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":821345744,"gmtCreate":1633701945854,"gmtModify":1633701945967,"author":{"id":"4092740792654610","authorId":"4092740792654610","name":"Winalot","avatar":"https://static.tigerbbs.com/8b310145827ffdca4a18cd3a698ce65e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Come come come. More good news please","listText":"Come come come. More good news please","text":"Come come come. More good news please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/821345744","repostId":"1198728824","repostType":4,"isVote":1,"tweetType":1,"viewCount":564,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":608743078,"gmtCreate":1638795194963,"gmtModify":1638795951176,"author":{"id":"4092740792654610","authorId":"4092740792654610","name":"Winalot","avatar":"https://static.tigerbbs.com/8b310145827ffdca4a18cd3a698ce65e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Congrats ","listText":"Congrats ","text":"Congrats","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/608743078","repostId":"608195827","repostType":1,"repost":{"id":608195827,"gmtCreate":1638661527701,"gmtModify":1638704925237,"author":{"id":"3583908378875163","authorId":"3583908378875163","name":"Hansen77","avatar":"https://static.tigerbbs.com/ce6fe6bb3c85a7f6f1d96e2469d290b4","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>This is my Apple share.","listText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>This is my Apple share.","text":"$Apple(AAPL)$This is my Apple share.","images":[{"img":"https://static.tigerbbs.com/7a8dd3644d1ba34067f4421ee50a6e74","width":"1080","height":"1920"}],"top":1,"highlighted":2,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/608195827","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":458,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}